相关实验视频

Updated: Jun 11, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

装甲仿真抗原受体T细胞的治疗点在导航瘤微环境中的T细胞

Xianjun Li^1,2,3, Tianjun Chen^1,3, Xuehan Li^1,4,3

¹Harbin Medical University Cancer Hospital, Harbin, 150081, China.

Experimental hematology & oncology

|October 1, 2024

概括

第四代仿真抗原受体 (CAR) T细胞疗法,或装甲CAR-T细胞,显示出治疗固体瘤的前景. 这种先进的免疫疗法在瘤微环境中导航,以提高CAR T细胞的疗效.

科学领域:

免疫治疗是一种免疫疗法.
在瘤学瘤学.
细胞疗法细胞疗法

背景情况:

化学抗原受体 (CAR) T细胞疗法对血液癌症非常有效.
之前的CAR T细胞代因瘤微环境和目标稀缺性而面临治疗固体瘤的挑战.
固体瘤治疗仍然是CAR T细胞治疗的一个重大障碍.

研究的目的:

对第四代CAR-T细胞 (装甲CAR-T细胞) 的当前治疗目标进行审查.
探索装甲CAR-T细胞如何在瘤微环境中导航和准组件.
讨论克服挑战的策略,并确定固体瘤治疗的新目标.

主要方法:

文献综述专注于第四代CAR T细胞技术.
对装甲CAR-T细胞用于克服瘤微环境障碍的机制的分析.
对固体瘤的新型治疗标和策略的探索.

主要成果:

第四代CAR-T细胞被设计为增强瘤微环境中的导航和准.
装甲的CAR-T细胞显示出对抗固体瘤的提高疗效的潜力.
确定特定的目标和策略,以增强固体瘤中CAR T细胞的功能.

结论:

第四代CAR-T细胞为增强固体瘤免疫治疗提供了一个有希望的方法.
向瘤微环境对于改善CAR T细胞持久性和透是至关重要的.
对新目标和策略的进一步研究将推动对固体恶性瘤的CAR T细胞疗法.

关键词:

癌症免疫疗法癌症免疫疗法化学抗原受体 (CAR) T 细胞固体瘤是一个固体瘤.在T细胞工程方面,T细胞工程瘤微环境是一个微环境.

更多相关视频

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...